In summary, with a focus on B-ALL due to the greater need for improved therapies compared to CML, which in most patients is well controlled by treatment with tyrosine kinase inhibitors17—these results suggest that microenvironmental ANXA2 deficiency attenuates induction of BCR-ABL1+ B-ALL, possibly due to inhospitality of the BMM. Here, ANXA2 is linked to acute lymphoblastic leukemia.